Health Care [ 6/12 ] | Biotechnology [ 45/74 ]
NASDAQ | Common Stock
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.
The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma.
It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors.
In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme.
The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds.
Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 13, 24 | -0.29 Decreased by -38.10% | -0.18 Decreased by -61.11% |
| May 8, 24 | -0.23 Decreased by -4.55% | -0.20 Decreased by -15.00% |
| Mar 27, 24 | -0.20 Increased by +81.13% | -0.23 Increased by +13.04% |
| Nov 9, 23 | -0.20 Increased by +31.03% | -0.22 Increased by +9.09% |
| Aug 10, 23 | -0.21 Increased by +30.00% | -0.24 Increased by +12.50% |
| May 15, 23 | -0.22 Increased by +29.03% | -0.31 Increased by +29.03% |
| Mar 23, 23 | -1.06 Decreased by -307.69% | -0.32 Decreased by -231.25% |
| Nov 9, 22 | -0.29 Increased by +36.96% | -0.31 Increased by +6.45% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 0.00 Decreased by N/A% | -35.02 M Decreased by -19.21% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 5.58 M Increased by +N/A% | -29.70 M Increased by +77.51% | Decreased by -532.28% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -30.36 M Increased by +12.55% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -31.78 M Increased by +10.00% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -29.37 M Increased by +19.33% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -132.08 M Decreased by -333.55% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -34.72 M Increased by +24.64% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -35.31 M Decreased by -25.15% | Decreased by N/A% Decreased by N/A% |